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RESUMO 
O sistema vascular permite a distribuição adequada de sangue e consequente fornecimento de oxigénio e 
nutrientes a todos os tecidos em vários organismos multicelulares. O sistema vascular é essencial para o 
desenvolvimento embrionário, o crescimento de tecidos e o processo de cicatrização. De especial interesse, 
muitas doenças que afectam o ser-humano, como por exemplo retinopatia diabética, isquemia, acidente 
vascular cerebral e crescimento de tumores sólidos, surgem devido a má formação e disfunção dos vasos 
sanguíneos. 
A formação de uma rede vascular funcional requer a extensão dos vasos sanguíneos pré-existentes pelo 
processo de angiogénese de forma a alcançar os tecidos não vascularizados e, em simultâneo, a remodelação 
do plexo vascular primitivo amorfo criado por angiogénese numa rede hierarquizada de artérias, veias e 
capilares. Estes dois processos são fortemente regulados pela comunicação molecular entre as células dos 
tecidos e as células endoteliais (as células que revestem os vasos sanguíneos). De especial relevância, começa 
agora a ser evidente que as células endoteliais necessitam de coordenar os seus comportamentos individuais 
para permitir a organização de uma rede vascular de forma coerente e funcional. É, por isso, importante 
compreender os mecanismos moleculares de regulação do comportamento coordenando das células 
endoteliais durante as diferentes fases do processo de formação dos vasos sanguíneos, sendo que isso irá 
certamente criar novas possibilidades de tratamento médico de várias doenças vasculares e melhorar o impacto 
das terapias existentes na saúde humana. 
Nos últimos anos temos assistido a um aumento significante tanto no desenvolvimento como no uso de 
tecnologias transgénicas, usadas em estudos que visam a nossa compreensão dos mecanismos biológicos, mas 
que têm também facilitado o desenvolvimento de uma vasta panóplia de modelos de doenças que têm grande 
impacto na abordagem das patologias humanas. As células estaminais embrionárias derivam de células 
totipotentes embrionárias e, como tal, servem como fonte putativa de vários tipos de células diferenciadas, 
dando origem a todos os tipos celulares do organismo. Existem duas características que distinguem as células 
estaminais embrionárias das restantes: a sua pluripotência e a sua capacidade de auto-renovação sob 
determinadas condições e, como tal, quando geneticamente modificadas in vitro, podem ser utilizadas no 
estudo de vários mecanismos biológicos em diferentes ensaios. Particularmente, as células estaminais 
embrionárias podem ser utilizadas em ensaios sobre angiogénese a partir da criação de corpos embrióides, que 
resultam da agregação in vitro destas células e que permitem testar o potencial das mesmas. A principal 
vantagem deste sistema, neste contexto, é poder ser manipulado a partir da utilização de células estaminais 
embrionárias distintas com diferentes modificações ou origem genética, criando quimeras que permitem a 
visualização da dinâmica das células endoteliais e o estudo da eficiência das diferentes fases do processo de 
formação dos vasos sanguíneos durante a angiogénese. 
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As tecnologias correntemente desenvolvidas para inserir um gene numa célula viva estão limitadas pela 
natureza aleatória desta inserção no genoma da mesma. O novo gene, ao ser posicionado arbitrariamente, pode 
inactivar ou perturbar o funcionamento de genes endógenos, causando efeitos indesejados na célula. 
Adicionalmente, estas tecnologias não permitem a reprodutibilidade do processo uma vez que não há garantia 
de que a nova sequência seja inserida na mesma posição do genoma em duas células diferentes. Este problema 
pode ser contornado utilizando tecnologias que permitem recombinação homóloga, na inserção de transgenes 
em locais específicos ou em modificações in situ de genes existentes, mas que são muito morosas pela 
necessidade de alcançar e seleccionar os clones positivos. 
De forma ultrapassar as dificuldades supramencionadas, pretendemos aumentar a eficiência e velocidade do 
processo de inserção de genes em células a partir do desenvolvimento de um método de fácil utilização para a 
manipulação de células estaminais embrionárias para o estudo em corpos embrióides. Para tal, pretendemos 
recorrer à actividade de um tipo de enzimas específico que reconhece curtas sequências de ADN que medeia a 
recombinação entre estes elementos, resultando em excisão, integração, inversão e substituição dos 
fragmentos de ADN, as chamadas site-specific recombinases (de sequência específica). Dentro desta família de 
enzimas, existe uma, a integrase PhiC31, que por recombinação homóloga e através de locais específicos de 
fixação, consegue integrar um fragmento de ADN de qualquer dimensão, de forma específica e irreversível. Com 
base neste mecanismo, desenvolvemos dois vectores, cada um deles com os locais de fixação específicos, sendo 
que um deles possui o genoma alvo e o segundo, o gene que pretendemos introduzir na célula. Através da 
expressão endógena de integrase PhiC31, a sequência de interesse será introduzida no genoma da célula de 
forma específica e eficiente, prevenindo a disrupção de genes endógenos e oferecendo perfeita 
reprodutibilidade. 
A principal vantagem desta ferramenta para o nosso laboratório prende-se com o facto de facilitar a 
manipulação de células estaminais embrionárias, que permitem a criação de corpos embrióides quiméricos para 
a visualização da dinâmica das células endoteliais e a eficiência de migração durante o processo angiogénico. 
Até ao momento a nossa estratégia revelou ser promissora, tendo a expressão de integrase PhiC31 sido bem-
sucedida em células cancerígenas em cultura mas, faltando ainda concluir a validação do vector de expressão, 
que revelou deformidades. A próxima fase será extrapolar a técnica para células estaminais embrionárias para 
que seja aprovada e posteriormente aplicada a diferentes ensaios em outras áreas da biologia. 
 
 
Palavras-Chave: Vasos Sanguíneos, Rede Vascular, Angiogénese, Células Endoteliais, Células Estaminais 
Embrionárias, Corpos Embrióides, integrase PhiC31. 
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ABSTRACT 
The established transgenesis methods used in embryonic stem cells allow efficient genomic integration of 
transgenes. However, the integration of multiple copies or transgenes at random genomic locations complicates 
comparative transgene analysis and makes long-term transgene stability unpredictable with variable expression. 
Targeted, site-directed transgene integration into pre-determined genomic loci can circumvent these issues, 
enabling direct comparison of different transgenes, thereby improving time and cost efficiency. The PhiC31 
integrase catalyzes the unidirectional recombination reaction between heterotypic attP and attB sites and is an 
efficient platform for site-directed transgenesis. 
Here, we implemented an efficient PhiC31-based site-specific transgenesis system for embryonic stem cells to 
be used in embryoid bodies’ studies. It allows the recombination of attB-containing transgene vectors into single 
genomic attP landing sites being this enzyme endogenously expressed by the cell, avoiding PhiC31 integrase 
encoding mRNA injection. Our strategy revealed a great potential as, cancer cells in culture were able to express 
PhiC31 integrase but, the validation of the expression vector is still ongoing due to deformities in the plasmid. 
The next step will be validating the technique in embryonic stem cells. 
The major advantage of this system for our laboratory is that it can easily be manipulated by using different 
transgenic embryonic stem cells, creating chimeras to visualize the dynamics of endothelial cells and study the 
efficiency of sprouting and migration during angiogenesis. 
This tool can also be applied to many other assays in transversal fields of biology. We hope that our results help 
researchers to optimize genome editing in their specific systems. 
 
 
 
 
 
 
 
 
Keywords: Blood Vessels, Vascular Network, Angiogenesis, Endothelial Cells, Embryonic Stem Cells, Embryoid 
Bodies, PhiC31 integrase. 
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1. INTRODUCTION 
Blood vessels have being studied for many centuries and even though we now know some of the molecular 
mechanism controlling the aspects that make the vascular system a very complex, stereotyped and hierarchical 
network, there are still a lot of unanswered questions behind the blood vessel formation. Importantly, the 
formation and maintenance of a functional vascular network is fundamental for growth and development of 
multicellular organisms as an incorrect vascular assembly is linked to several pathological states such as solid 
tumors, cerebral cavernous malformations, hemangiomas, retinopathies and arteriovenous malformations.  
The first vessels in the developing embryo form through vasculogenesis, after which angiogenesis, the 
physiological process through which new blood vessels form from pre-existing ones, is responsible for most, if 
not all, blood vessel growth during development and in disease. During sprouting angiogenesis, there are two 
distinct types of cells, the tip and stalk cells, whose phenotype is known to be regulated by a VEGF/Notch 
signaling. 
In the past years, we have witnessed a significant increase in both the development and use of transgenic 
technologies that have been used to aid our fundamental understanding of biologic mechanisms, but that have 
also facilitated the development of a range of disease models that have a huge impact upon our approach to 
human disease. Embryonic stem cells are derived from totipotent cells of the embryo and therefore, can serve 
as a putative source of numerous types of differentiated cells, thus generating every cell type in the body. Two 
distinctive properties distinguish embryonic stem cells, their pluripotency and their capacity for self-renewal 
under defined conditions. Embryonic stem cells can be genetically modified in vitro and thus be used to study 
many different mechanisms in different assays, particularly, they are used in sprouting assays by creating 
embryoid bodies. Embryoid bodies are the result of the in vitro aggregation of embryonic stem cells and are 
utilized to test the differential potential of these cells. The major advantage of this system for our laboratory is 
that it can be manipulated by using different embryonic stem cells with different modifications or distinct 
genetic background, creating a chimera (a single organism composed of genetically distinct cells) to visualize the 
dynamics of endothelial cells and study the efficiency of sprouting and migration during angiogenesis. 
The current technologies used to insert a gene into a living cell are limited by the random nature of the insertion 
of the new sequence into the genome. The new gene is positioned arbitrarily, and may inactivate or disturb the 
functioning of other genes or even cause severe unwanted effects. Furthermore, these technologies offer no 
degree of reproducibility, as there is no guarantee that the new sequence will be inserted at the same place in 
two different cells. The precise genetic modification can be achieved in embryonic stem cells by taking 
advantage of homologous recombination to target single-copy transgenes to specific sites or to modify existing 
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genes in situ, but this technique is very time-consuming because it is necessary to target and select the positive 
clones.  
Site-specific recombinases recognize short DNA sequences (typically between 30 and 40bp) and mediate the 
recombination between these elements resulting in excision, integration, inversion, or exchange of DNA 
fragments. The PhiC31 integrase is a sequence-specific recombinase that by homologous recombination and 
using attachment (att) sites, can integrate a plasmid of any size in an irreversible way. Taking advantage of these 
properties and in order to overcome the difficulties inherent to the existing methods for cell genome 
manipulation, we developed a way to easily manipulate embryonic stem cells to test embryoid bodies, 
increasing the efficiency and speed of the clone selection process.  
We created two vectors, one with the target genome and the other with the protein that we want to express. 
Each of the vectors has a PhiC31 attachment site and, through the endogenous expression of PhiC31 integrase, 
induced by the first vector, the expression plasmid is inserted in the genome of the cell, in a specific and 
efficient way. The major advantages of this system is that it enables a specific area of the DNA to be modified, 
thereby increasing the precision of the correction or insertion, preventing any cell toxicity and offering perfect 
reproducibility. At the moment, our strategy revealed to have potential as the insertion of the targeting vector 
in U2OS cells in culture worked well and cells are expressing PhiC31 integrase but, we were still not able to 
create an expression vector able to confirm the efficiency of our technique. The next step is to test the 
constructs in embryonic stem cells to validate it so it can, posteriorly, be applied to different systems of other 
fields of biology. 
This study took place at the Vascular Morphogenesis Laboratory, in Instituto de Medicina Molecular, Lisbon, and 
was performed under the supervision of Dr. Cláudio Areias Franco, group leader of the laboratory that is mainly 
focused on the understanding of the molecular mechanisms regulating coordinated endothelial cell behavior 
during sprouting and remodeling phases of the angiogenic process. Improving the knowledge on the molecular 
regulation of vascular morphogenesis will certainly create new possibilities for medical prevention and 
treatment of various human conditions. 
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2. BACKGROUND 
The correct development of blood vessels is essential for all aspects of tissue growth and physiology in 
vertebrates as they supply oxygen and nutrients to the organism. In the adult, vessels are normally quiescent; 
however, structural or functional vessel abnormalities may occur. An inadequate vessel maintenance or growth 
causes ischemia in diseases such as myocardial infarction, stroke, and neurodegenerative or obesity-associated 
disorders, whereas excessive vascular growth or abnormal remodeling promotes many ailments including 
cancer, inflammatory disorders, and eye disease [1][2]. The formation of an elaborate hierarchically branched 
vascular network, through either vasculogenesis or angiogenesis, relies on a series of coordinated morphogenic 
events that involves complex and highly dynamic interactions between endothelial cells and their environment.  
In the embryo, new vessels form de novo via the assembly of mesoderm-derived endothelial precursors, 
angioblasts, that differentiate into a primitive vascular network, in a process called vasculogenesis [3]. The 
subsequent sprouting from the pre-existing vessels, angiogenesis, leads to the stabilization of that network 
remodeling it into arteries, veins and capillaries [4] thus creating the complex, hierarchical and functional 
vascular network and we know, allowing the correct blood supply to all tissues.  
2.1. SPROUTING ANGIOGENESIS 
In order to constantly respond to metabolic and growth demands, the vascular system is highly dynamic and 
endothelial cells are able to sense and respond to the environmental signals, initiating the angiogenic process. 
Biological signals such as hypoxia, ischemia and/or blood vessel damage, promote the upregulation of pro-
angiogenic factors and, attracted by these factors, endothelial cells become motile and invasive by protruding 
filopodia that guide the new blood vessel in a certain direction (see Figure 1A). These so-called tip cells lead new 
sprouts and probe the environment for guidance cues. Following tip cells, stalk cells are able to proliferate to 
support sprout elongation and establish the vessel. These two cell types constitute the so-called vascular sprout, 
which remains connected to the original vessels while migrating into the avascular tissue. Tip cells anastomose 
with cells from neighboring sprouts to build vessel loops and the posterior initiation of blood flow, 
establishment of a basement membrane, and recruitment of mural cells stabilize the new connections (see 
Figure 1B and C). The iteration of the sprouting process continues until pro-angiogenic signals cease, and 
quiescence is re-established. 
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Figure 1. Schematic model of sprout initiation, vessel branching, and maturation. (A) Angiogenesis is activated in response to local growth 
factors, that (re)activates the quiescent endothelial cells differentiates them into tip and stalk cells. (B) Endothelial cells proliferate and 
collectively invade the tissue while remaining connected to the original vascular network and the tip cells contact other sprouts. (C) The new 
connection between different sprouts occurs through tip cell fusion (anastomosis) and the formation of the vascular lumen initiates blood 
flow. As a functional vessel loop is formed, there is a reduction of the release of endothelial growth factors, supporting the establishment of 
quiescence.  Image adapted from [5]. 
2.1.1. VEGF AND NOTCH/DLL4 SIGNALING PATHWAYS 
The specification of endothelial cells into tip and stalk cells within the activated endothelium is determined by 
the feedback loop between VEGF and Notch1/delta-like ligand 4 (Dll4) signaling pathways [6][7]. The resulting 
cell-fate specification mechanism is based on a Notch-mediated lateral inhibition process, in which a cell 
becomes tip cell and prevents its immediate neighbors from acquiring the same phenotype. This cell adopts this 
phenotype due to stochastic differences in local vascular endothelial growth factor (VEGF) concentrations, in 
filopodia elongation (and thus VEGF exposure) or in transcription rate that leads to small imbalances where one 
cell will express slightly higher Dll4 levels and, thus, dominate its neighbors by activating more Notch signaling 
[8][9]. The cell with more Dll4, and less Notch activity, will be selected as the tip cell. The activation of Notch 
inhibits VEGF receptor 2 (VEGFR2), indirectly inhibiting Dll4 expression levels, thereby reinforcing the 
dominance of the selected tip cell and limiting the number of tip cells induced by VEGF (see Figure 2) [10][11].  
Besides downregulating VEGFR2, Notch signaling also affects VEGFR1 and VEGFR3 expression. Notch activation 
leads to increased levels of VEGFR1. This reduces the angiogenic sprouting response to VEGF, as both receptor 
variants act as a decoy for the VEGF ligand and limit VEGFR2 activation [12][13]. VEGFR3 is most strongly 
expressed in the leading tip cells and is downregulated by Notch signaling in the stalk cells [14]. Collectively, 
these molecular regulatory processes lead to increased responsiveness of the tip cell to VEGF and decreased 
sensitivity of stalk cells to this factor.  
A B
v
d 
C
v
d 
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Recent observations challenge the idea of stable tip and stalk cell selection as their phenotype revealed to be 
dynamic and transient, relying on continued competition between the cells within blood vessel sprouts [15]. As 
a consequence, tip cells are overtaken and exchanged by neighboring stalk cells. 
2.1.2. COMPETITION BETWEEN TIP AND STALK CELLS 
Recent time-lapse imaging studies have shown the dynamic shuffling between tip and stalk cells at the leading 
front of growing sprouts, both in vitro (in embryoid bodies sprouting assays) and in vivo (in mice and zebrafish). 
The positional exchange suggests that the cells have constantly to reevaluate the VEGF/Notch signaling loop 
when they contact new neighboring cells, competing for the tip cell position based on their relative levels of 
VEGFR1 and VEGFR2. These receptors’ activities mediate the expression level of the Dll4 ligand: lower 
expression levels of VEGFR1 or higher levels of VEGFR2 result in higher levels of Dll4 expression and, hence, an 
increased ability of a cell to suppress its neighboring cells from becoming tip cells [15]. This proposes that the tip 
cell is constantly challenged by cells within the stalk cell region of the sprout to demonstrate its dominance in 
terms of VEGFR levels, ensuring that the cell with the best guiding capacities leads the sprout.  
Figure 2. Tip to stalk cell lateral inhibition during sprouting angiogenesis. VEGF interacts with VEGFR2, expressed at the surface of the 
endothelial cells of the quiescent vessels. The VEGF signaling output is modulated, enhancing the binding activity and signaling of VEGF 
through VEGFR2. Under VEGF stimulation, Dll4 expression is up-regulated in the tip cells. In turn, Dll4 ligand activates Notch signaling in the 
stalk, consequently suppressing the tip cell phenotype. Notch signaling activation reduces VEGFR2 expression and increases 
VEGFR1/sVEGFR1 as well as the expression of different Notch target genes. In contrast, the tip cell receives low Notch signaling, allowing 
high expression of VEGFR2 but low VEGFR1. Image adapted from [5]. 
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2.1.3. EMBRYOID BODY SPROUTING ASSAY AS A TOOL TO MEASURE CELL COMPETITION     
Embryonic stem (ES) cells are pluripotent cells derived from blastocyst-stage early mammalian embryos that are 
capable of differentiation into all three germ layers and, therefore, have the potential to develop any type of 
tissue. Because of this particular characteristic, the maintenance and differentiation of embryonic stem cells 
contributed greatly to significant discoveries in developmental biology. When cultured in suspension without 
anti-differentiation factors, embryonic stem cells spontaneously differentiate and form three-dimensional multi-
cellular pluripotent aggregates called embryoid bodies (EBs) [16]. This structure facilitates multicellular 
interactions, in which cell-cell contact exists, and consists of a mix of cell populations with ectodermal, 
mesodermal, and endodermal origins. Embryoid body’s aggregates recapitulate many aspects of cell 
differentiation during early mammalian embryogenesis offering the opportunity to mechanistically study these 
differentiation events of tridimensional assemblies of pluripotent cells with the great advantage that genetic 
manipulation of endothelial stem cells can be studied for gene mutations or knockouts that prove to be lethal 
during normal embryonic development in vivo [17]. As differentiation continues, a wide range of cell types are 
developed within the embryoid body’s environment and, consequently, this technique has been widely utilized 
as a trigger during the process of embryonic stem cells differentiation in vitro. The embryoid bodies’ potential 
covers different research fields and several gene knockout studies have being made using this technique. For 
example, embryoid bodies were used as an alternative for studying hematopoiesis [18][19], for complementary 
studies of cardiomyocytes differentiation [20] and for accessing endothelial cells behavior [21][22]. Currently, 
there are several methods with unique peculiarities used to form embryoid bodies from embryonic stem cells 
that allow for different objectives to be attained [23][24]. 
2.1.3.1. ASSESSING SPROUTING CAPACITY, DYNAMICS AND COMPETITION OF CELLS 
The embryoid body model is valuable to easily access vessel development, by manipulation and visualization at a 
high resolution as the endothelial cell conventional cultures do not provide a proper microenvironment for it. 
Three dimensional models allow studying interactions between endothelial cells, adjacent non-endothelial cells 
and matrix, which are known to be essential in the regulation of vascular processes, as well as the metabolism 
and sprouting efficiency of these cells. 
The sprouting capacity of endothelial cells during sprouting angiogenesis can be visualized by using embryoid 
bodies by designing a mosaic sprouting assays using embryonic stem cells. These cells, as said before, are able to 
form embryoid bodies that, when cultured in a solidified collagen matrix and treated with VEGF, exhibit robust 
differentiation into the endothelial cell lineage and an angiogenic behavior that resembles the major steps of 
sprouting angiogenesis in vivo [25][26].  
Previous work described that chimeric cultures of embryonic stem cell, originated from 1:1 mixtures of two 
wild-type embryonic stem cell lines, revealed mosaic vascular sprouts. Deeper analysis of the genotypic origin of 
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the leading tip cells have shown an equal participation of each cell population to the leading tip cells, proving 
that wild-type cells of different genetic background have equal potential to acquire the tip cell phenotype (see 
Figure 3A and B)[15]. 
To investigate the interactions between cells in the selection process and the role of VEGFR levels in it, the same 
group studied different combinations of endothelial cells with half the amount of VEGFR1 or VEGFR2 competing 
with wild-type neighboring cells for the leading position [15]. It was shown that endothelial cells derived from 
embryonic stem cells heterozygous for the Vegfr2 allele (Vegfr2
+/egfp
, that exhibited approximately half the 
VEGFR2 levels, comparing to wild-type cells), when mixed with wild-type cells in a 1:1 ratio in mosaic cultures, 
contributed to only around 13% of the tip cells, showing that reduced Vegfr2 levels selectively impair the ability 
of cells to acquire the tip phenotype. When varying Vegfr1 levels using chimeric cultures of wildtype and 
Vegfr1
+/lacz
 embryonic stem cells (that exhibited approximately half the VEGFR1 levels in comparison to wild-
type cells), 70% of the tip cells were derived from the Vegfr1 heterozygote population. This demonstrates that a 
cell with lower Vegfr1 expression has a higher probability of acquiring the leading position, whereas a cell with 
lower Vegfr2 expression has reduced ability to take the lead, when competing with a wild-type neighboring cell, 
suggesting that the balance of VEGFR2 and VEGFR1 expression in individual endothelial cells affects their 
potential to become tip cells during sprouting angiogenesis (see Figure 3). 
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Figure 3. VEGFR levels in mosaic-tip-cell selection in vitro. (A, B) Sprouting vasculature (green) of a chimeric embryoid body composed of 
two different wild-type strains, immunolabelled with antibodies specific to CD31. One strain has ubiquitous expression of the fluorophore 
DsRed-MST (tip cells indicated by red arrowheads) and the other one is a non-fluorescent embryonic stem cell line (R1) (tip cells indicated 
by green arrowheads). (C, D) Chimeric embryoid body of wild-type (red) and Vegfr2 heterozygote cells (Vegfr2+/egfp, green) mixed in a 1:1 
ratio. Wild-type tip cells are indicated by red arrowheads, Vegfr2+/egfp tip cells are indicated by green arrowheads. (E, F)  Chimeric 
embryoid body of wild-type cells (red; tip cells are indicated by red arrowheads) and Vegfr1 heterozygote cells (tip cells are indicated by 
green arrrowheads), mixed in a 1:1 ratio. (G) Quantification of tip cells with the indicated genotype in chimeric embryoid bodies. Number 
of counted tip cells per condition: 630–708 (n embryoid bodies per condition = 6, WT:WT; 11, WT:vegfr2+/egfp; 9, WT:vegfr1+/lacz). Values 
represent means ± s.e.m. Scale bars: a, c, e, 200μm; b, d, f, 20μm. Image adapted from [15]. 
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Despite embryonic stem cells and embryoid bodies assays’ great potential and usefulness for this kind of 
studies, there is a limited number of genetically modified cell lines available. This results in a gap where knock-
downs of genes, expression of fluorescent reporters and overexpression of specific isoforms, including 
fluorescently-tagged proteins, point mutations forms and dominant-negative/active isoforms are lacking. 
2.2. HOW TO MANIPULATE STEM CELLS 
Embryonic stem cells have one great advantage over other cell types that is their accessibility to genetic 
manipulation. These cells are able to remain pluripotent after genetic modifications and so, they are widely used 
and there is a range of effective techniques that have been established for gene delivery and manipulation of 
embryonic stem cells. These methodologies include electroporation, transfection and infection protocols, and 
also different approaches for inserting, deleting, or changing the expression of genes. 
2.2.1. GENETIC ENGINEERING 
The strategies used in genetic engineering usually require the permanent modification of the target genome. 
For this to happen, the insertion of a construct into the genome of the cell needs to be stable but the prevailing 
approaches for this over the last years have been based in methods that lead to a random integration. 
Randomly integrating technologies enable users to create stable systems leading to lasting expression which 
results in a random insertion of selected DNA fragments into the host genome without the use of DNA 
homology. Besides providing a valuable tool for long-term expression in embryonic stem cells, random insertion 
leads to inconsistent integration sites and unpredictable expression patterns. In addition, the locus of insertion 
can result in partial or complete silencing of endogenous genes of embryonic stem cells, which can result in 
insertional mutagenesis with subsequent genome instability or toxicity [27][28]. 
Site-specific modification is an ideal method to avoid variable expression patterns and copy number variation as 
a result of random integration. These tools enable the targeting of specific sites within the chromosome where 
silencing is minimized. Gene targeting using traditional methods via homologous recombination has been 
extensively used to specifically alter genes. This method involves the introduction of a targeting construct 
homologous to the target gene sequence of the embryonic stem cell [29]. Despite offering, in principle, great 
specificity to the integration process, homologous recombination has an extremely low efficiency and is very 
laborious. With this in mind, new strategies have been developed to achieve integration at predetermined 
target sites with high efficiency, based on site-specific recombinases like Cre, FLP and PhiC31 integrase.  
2.2.1.1. SITE-SPECIFIC RECOMBINASES 
Site-specific recombinases (SSRs) are highly specialized enzymes that perform rearrangements of DNA 
fragments by recognizing and binding to short DNA sequences, sites. Recombination sites are typically between 
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30 and 200 nucleotides to which the recombinase binds, flanking a central crossover sequence at which the 
recombination takes place [30][31][32].  
FLP and Cre recombinases belong to the integrase family of recombinases (also termed “λ integrase” family) and 
do not need any accessory factors to mediate recombination. The FLP recombinase (FLP) recognizes FRT sites 
and mediates recombination between them [33]. The Cre (causes recombination) recombinase recombines loxP 
(locus of crossover (×) in P1) target sites [34] and shares the common integration mechanism with FLP. A 
considerable limitation of both the FLP/FRT and the Cre/loxP system exists when used for integration and 
inversion. In both cases two identical target sites (homotypic sites) are present in close proximity after the 
recombination event, which then can serve again as substrates for a further recombination event, i.e., for 
excision or reinversion. In other words, FLP and Cre are “bidirectional” recombinases. Because excision reactions 
are kinetically favored over integrations, the integrated DNA is highly unstable [35]. 
The integrase of the Streptomyces phage PhiC31 normally 
mediates the integration of the phage genome [36] into the 
bacterial chromosome through heterotypic recombination 
sites, termed attB (attachment site Bacterium) and attP 
(attachment site Phage) sites, and like FLP and Cre, it does 
not need any accessory factors to mediate this integration 
[37]. The two sequences, though largely different, share a 
3bp central region, where the crossover occurs, and this 
central region is flanked by imperfect repeats. 
Recombination between the two attachment sites creates 
the hybrid sites attL and attR (Left and Right) that are no 
longer substrates for the PhiC31 integrase, thus rendering 
the recombination irreversible (see Figure 4) [38][39]. This 
distinguishes it from Cre and FLP, and thus the PhiC31 
integrase, as a unidirectional recombinase, is an efficient 
tool to insert transgenes into a genome [40][41]. This 
recombination system was successfully applied in bacteria 
[37], yeast [42], mammalian cell lines [41] [43], Xenopus 
[44], Drosophila [45][46][47] and plants [48][49] and so, the 
PhiC31-based transgenesis has become widely used. In this 
technique, the attB site-containing vectors are co-injected with PhiC31 integrase encoding mRNA into embryos 
that harbor a previously introduced transgenic attP site in their genome. The enzyme will then recombine the 
vector attB with the genomic attP sites, resulting in the integration of the full transgene vector into the genomic 
Figure 4. PhiC31 Integrase System. The phiC31 integrase 
mediates recombination between the two attachment sites. 
In the presence of PhiC31 integrase, an attB-containing donor 
plasmid can be unidirectionally integrated into a target 
genome through recombination at sites with sequence 
similarity to the native attP site. 
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attP locus with high efficiency, regardless of its size. The well-characterized integration sites eliminate time and 
effort to map transgene insertions and eliminate the need for several independent lines per transgene, thus 
effectively reducing the space requirement and workload of generating, analyzing, and maintaining transgenics. 
Although site-specific recombination systems are diverse, the common property that makes these enzymes so 
attractive (the ability to specifically and autonomously integrate, excise, or invert defined sequences of DNA) 
also limits their practical utility. Site-specific recombinases are involved in essential biological functions, what 
demonstrates their strict specificity toward their natural target. Indeed, the use of these enzymes in mammalian 
cells requires, either the presence of rare pre-existing recognition sites or the previous introduction of specific 
target sites within the host genome by homologous recombination [40][50]. Therefore, besides site-specific 
recombinases potential as transformative tools for targeted genetic engineering, their application is conditioned 
by technical constraints. In order for this technology to reach its full potential, methods for the enhancement 
and design of custom recombinases capable of modifying specific DNA sequences are required. 
2.2.1.2. CRISPR/CAS9 
Recently, a new class of genome engineering tools was reported and it has provided a much simpler and more 
economic method for gene-targeted modification, the CRISPR/Cas9 system. This follows the previous efforts in 
genetic manipulation, including homologous recombination [51] and RNA interference (RNAi) [52]. Other recent 
approaches to targeted genome modification, like zinc-finger nucleases (ZFNs) [53] and transcription-activator 
like effector nucleases (TALENs) [54], enable researchers to generate permanent mutations by introducing 
double-stranded breaks to activate repair pathways but are costly and time-consuming approaches, limiting 
their general use. The clustered regularly interspaced short palindromic repeats (CRISPR) are unique sequences 
in between DNA repeats that naturally occur and were shown to play an essential role in immunity of selected 
bacteria and archaea, enabling the organisms to respond to and eliminate invading genetic material. These 
repeats were initially discovered in the 1980s in E. coli [55], but their potential was only confirmed with the 
demonstration that S. thermophilus can acquire resistance against a bacteriophage by integrating a genome 
fragment of an infectious virus into its CRISPR locus [56]. 
There are three different types of CRISPR mechanisms, being type II the most studied. In this case, DNA from 
viruses or plasmids is cut into small fragments and integrated into a CRISPR locus among a series of short 
repeats. The loci are transcribed, and transcripts are then processed generating small RNAs (crRNA – CRISPR 
RNA), which are used to guide effector endonucleases that target invading DNA based on sequence 
complementarity [57]. This CRISPR mechanism distinguishes from the others as only one Cas protein (Cas9) is 
required for gene silencing. Cas9 (also known as Csn1), comes from Streptococcus pyogenes and has been 
shown, through knockdown and rescue experiments, to be a key player in this CRISPR system as it participates in 
the processing of crRNAs, and is responsible for the destruction of the target DNA. To achieve site-specific DNA 
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recognition and cleavage, Cas9 has to be complemented with a crRNA and a separate trans-activating crRNA 
(tracrRNA), partially complementary to the crRNA  [57][58]. More recently, researchers developed a simplified 
two-component system that combines tracrRNA and crRNA into a single synthetic single guide RNA (sgRNA). 
This mechanism was shown to be as effective as the original CRISPR in guiding targeted gene alterations [57]. 
To date, there are three variants of the Cas9 nuclease that have been implemented in genome-editing 
protocols. The first is the wild-type Cas9, which can site-specifically generate a DNA double-strand break at the 
targeted genome locus that activates repair through error-prone nonhomologous end joining or homology-
directed repair. In the absence of a template, the nonhomologous end joining is activated, resulting in insertions 
and/or deletions that disrupt the target loci. In the presence of a donor template with homology to the targeted 
locus, the homology-directed repair pathway operates, allowing for precise mutations to be made (see Figure 
5A) [59][60]. The second variant has increased precision and is a Cas9 mutant form, known as Cas9D10A, with 
only nickase activity. This means that it cleaves only one DNA strand, and does not activate nonhomologous end 
joining. Instead, when provided with a homologous repair template, DNA repairs are conducted via the high-
fidelity homology-directed repair pathway only, resulting in reduced insertion and/or deletion mutations (see 
Figure 5B) [57][61]. The last variant is a nuclease-deficient Cas9 (dCas9) with mutations in two specific Cas9 
domains that inactivate cleavage activity, but do not prevent DNA binding and therefore, this variant can be 
used to sequence-specifically target any region of the genome without cleavage [62][63], as a gene silencing or 
activation tool by fusing with various effector domains [64][65] and as a visualization tool, for instance, the 
fusion with enhanced green fluorescent protein (EGFP) allowed visualizing repetitive DNA sequences with a 
single sgRNA or nonrepetitive loci using multiple sgRNAs (see Figure 5C) [66].  
Figure 5. CRISPR/Cas9 genome engineering with Cas9 nuclease variants. (A) Wild-type Cas9 nuclease site specifically cleaves double-
stranded DNA. Non-homologous end joining can result in insertions/deletions disrupting the target sequence. Alternatively, precise 
mutations and knock-ins can be made by providing a homologous repair template and exploiting the homology directed repair pathway. (B) 
Mutated Cas9 makes a site specific single-strand nick. Two sgRNA can be used to introduce a staggered double-stranded break which can 
then undergo homology directed repair. (C) Nuclease-deficient Cas9 can be fused with various effector domains allowing specific 
localization. For example, transcriptional activators, repressors, and fluorescent proteins. Image adapted from [83]. 
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Besides being a faster alternative for cell genome manipulation compared to traditional gene targeting 
methods, the CRISPR/Cas9 system has some limitations. First, there is the possibility of off-site effects, when a 
mutation is introduced at non-specific loci with similar, but not identical, homology to the target sites. These can 
be difficult to identify and require scanning the genome for mutations at sites with sequence similarity to the 
sgRNA target sequence. Still, this mechanism has better targeting efficiency comparing with the previously 
established methods (TALENs or ZFNs) that, in human cells, were only able to achieve efficiencies ranging from 
1% to 50% [67][68]. In contrast, the Cas9 system has been reported to have efficiencies up to 70% in zebrafish 
and plants [69], and ranging from 2–5% in induced pluripotent stem cells [70]. In addition, other studies were 
able to improve genome targeting up to 78% in one-cell mouse embryos, and to achieve effective germline 
transmission through the use of dual sgRNAs to simultaneously target an individual gene [71]. Second, 
mosaicism can occur when nucleases do not cut the DNA at the one cell stage of embryonic development of a 
mouse line and when that happens, mice with a mutant allele in only some of their cells can be produced. 
Multiple alleles are another drawback of the technique, due to the fact that the healing of the nuclease cleavage 
site by non-homologous end joining can produce cohorts of mice with different mutations from the same 
targeting constructs, requiring genome sequencing to verify the nature and position of the specific mutation. 
The production of mice with mosaics of multiple mutations is also possible and breeding may be required to 
segregate and isolate mice that carry single mutations. 
Despite the limitations, the CRISPR/Cas9 system has been widely adopted and successfully used to target 
important genes in many cell lines and organisms, including human [70], bacteria [72], zebrafish [73], C. elegans 
[74], plants [70], Xenopus tropicalis [75], yeast [76], drosophila [77], monkeys [78], rabbits [79], pigs [74], rats 
[80] and mice [81]. This technique requires only the redesign of the crRNA to change target specificity, 
contrasting with other genome editing tools, where redesign of the protein-DNA interface is required. The rapid 
progress in developing Cas9 into a set of tools for cell and molecular biology research has been remarkable, 
likely due to the simplicity, high efficiency and versatility of the system. Of the designer nuclease systems 
currently available for precision genome engineering, the CRISPR/Cas system is by far the most user-friendly and 
its potential and usefulness seems to be unlimited. 
2.3. PURPOSE OF THIS THESIS 
Taking into account the difficulties that the previous established methods bring to the genome editing process, 
in this thesis we propose a new mechanism to insert a gene, of any size, into an embryonic stem cell in a fast 
and efficient manner. This will allow the easy and versatile manipulation of embryonic stem cells to create 
embryoid bodies and mouse lines that will posteriorly allow the study of several different mechanisms in 
transversal fields of biology. 
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3. MATERIALS & METHODS 
3.1. POLYMERASE CHAIN REACTION 
Polymerase chain reaction (PCR) is a cell-free technique, which is used to amplify a specific DNA sequence by in 
vitro enzymatic replication assisted by a DNA polymerase. In an exponential manner a small amount of DNA is 
amplified into a large amount of DNA in a very short period. The region comprised between the two selected 
primers is the region of interest to be amplified. The DNA containing the sequence to be amplified is incubated 
in a test tube with the primers, each complementary to the ends of the targeted DNA, the four 
deoxynucleotides and a DNA polymerase.  
The PCR process consists of a series of about 25-35 subsequent cycles and each cycle consists of three precisely 
time- and temperature-controlled steps (denaturation, annealing and extension). The first step separates the 
double stranded DNA into two single strands by use of a high temperature (95°C - 98°C, depending on the 
manufacturers’ indications). This denaturing step breaks the hydrogen bonds between the two strands. Then 
the temperature is lowered to the primers’ specific annealing temperature to allow them to base pair to their 
complementary sequences on the template strands. Further the reaction is heated to 72°C, the optimal 
temperature for the heat stable DNA polymerase to replicate the single stranded DNA segments. The DNA 
polymerase uses deoxynucleotides as building blocks of the new strands. 
PCRs were set up with either Phusion High-Fidelity DNA Polymerase from Thermo Scientific for DNA extraction 
or NZYTaq 2× Green Master Mix from NZYTech to identify positive clones using optimal reaction conditions 
according to the manufacturer’s protocol (see list of primers in the Appendix).  
Table 1. Component and cycling instructions for the PCR reactions.  The reagents pipetting information (left) and cycling conditions (right) 
for both Phusion High-Fidelity DNA Polymerase (top) and NZYTaq 2× Green Master Mix (bottom). X°C represents the annealing temperature 
of the primers used in the reaction. 
Components 50µL Reaction Final Concentration  Cycle Step Temperature Time Cycles 
H2O up to 50µL 
 
 Initial Denaturation 98°C 30sec 1 
5X Phusion HF Buffer 10µL 1X  Denaturation 98°C 5-10sec 
25-35 10 mM dNTPs 1µL 200µM each  Annealing X°C 10-30sec 
Forward Primer - 0.5µM  Extension 72°C 15-30sec 
Reverse Primer - 0.5µM  Final Extension 72°C 5-10min 1 
Template DNA - 1pg-10ng  
 
4°C hold 
 
Phusion DNA Polymerase 0.5µL 0.02U/µL  
    
   
 
    Components 20µL Reaction Final Concentration  Cycle Step Temperature Time Cycles 
H2O up to 20µL 
 
 Initial Denaturation 95°C 120sec 1 
Forward Primer - 0.5µM  Denaturation 95°C 30-60sec 
25-35 Reverse Primer - 0.5µM  Annealing X°C 30-60sec 
Template DNA - 0.01-0.5μg  Extension 72°C 60sec/kb 
NZYTaq 2× Green Master Mix 10µL 
 
 Final Extension 72°C 5-10min 1 
   
 
 
4°C hold 
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3.2. AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis was used to confirm each step of the cloning process and to separate PCR products 
to purify the desired DNA fragments. These fragments are separated by applying an electric field to move the 
negatively charged molecules through an agarose matrix that are separated by size in the agarose gel matrix. 
Shorter nucleic acid molecules move faster and migrate further than longer ones due to the fact that these drift 
more easily through the pores of the gel.   
The matrix used was 1% w/v% agarose dissolved in 1xTBE buffer (1M Tris-base, 1M Boric acid, 0.02M EDTA). 1kb 
DNA Ladder or 1kb Plus DNA Ladder from New England Biolabs was run in parallel to the samples and DNA Gel 
Loading Dye (6X) from Thermo Scientific was added to all samples before loading them in the gel (except in the 
case of reactions assembled with NZYTaq 2× Green Master Mix that may be directly loaded onto agarose gels). 
Electrophoresis was carried out in 1X TBE buffer at 100V for 40-60 minutes. Visualization of DNA was performed 
by exposure to UV-light using Chemidoc XRS+ (Bio-Rad) and the products of the reactions were confirmed by 
size comparison with the DNA ladder. 
3.3. DNA  EXTRACTION FROM AGAROSE GEL AND PURIFICATION 
Gel extraction is used to isolate the desired fragment of DNA from the agarose gel following electrophoresis. 
This technique involves identifying the fragments of interest, isolating the corresponding band, isolating the 
DNA from it and removing the accompanying salts and stain.  
The DNA fragments were visualized on a Dual-Intensity Transilluminator using the low setting of UV-light and 
the desired band was physically removed by cutting it out from the agarose gel with a clean scalpel. The 
extraction of the DNA fragments from the gel slice was performed using QIAquick® Gel Extraction Kit from 
Qiagen following the manufacturer’s protocol. DNA was eluted from the spin column using 30µL of dH2O. 
3.4. ETOH PRECIPITATION 
Ethanol precipitation is a commonly used technique to purify and/or concentrate nucleic acids (DNA or RNA) 
preparations in aqueous solution.  
For this procedure salt and ethanol are added to the aqueous solution (1/10 volume of sodium acetate (3M, pH 
5.2) and 2.5–3.0 X volume (calculated after addition of sodium acetate) of 96% ethanol), followed by a 2 hours 
incubation at -20°C, which forces the precipitation of nucleic acids out of solution. After precipitation the nucleic 
acids can then be separated from the rest of the solution by 20 minutes centrifugation at 4°C at 13000rpm. The 
pellet is washed in 200µL of cold 70% ethanol then after a further 15 minutes centrifugation at 4°C at 13000rpm 
the ethanol is removed, and the nucleic acid pellet is air dried before being resuspended. 
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3.5. DIGESTION OF DNA WITH RESTRICTION ENZYMES 
Restriction enzyme digestion takes advantage of naturally occurring enzymes that recognize specific sequences 
in DNA and cleave it at these specific sites. Restriction digestion of plasmid constructs provides a fast and cost-
efficient method of gaining indirect sequence information, giving insights for the presence or absence of an 
insert, orientation of the insert, plasmid size, and site-specific sequence data. This technique is also useful to 
produce a DNA fragment that can be cloned directly into a vector. Plasmid DNA is digested with one or more 
restriction enzymes selected to give a distinct DNA band pattern that is easily resolved by electrophoresis.  
DNA digestions were performed using restriction enzymes from New England Biolabs® or Thermo Scientific. 
Restriction enzyme digestions were performed under optimal conditions described by the manufacturer (see list 
of all the restriction enzymes in the Appendix). 
3.6. L IGATION OF DNA FRAGMENTS 
The ligation of DNA fragments is accomplished by covalently connecting the insert DNA (gene or fragment of 
interest) into a compatibly digested vector backbone and is mediated by a DNA ligase enzyme that catalysis the 
formation of covalent phosphodiester linkages, which permanently join the nucleotides together. This reaction 
involves DNA fragments that have been generated by restriction enzyme digestion. Most restriction enzymes 
digest DNA asymmetrically across their recognition sequence, resulting in a single stranded overhang on the 
digested end of the DNA fragment. The overhangs, called sticky-ends, when compatible, meaning that the 
overhanging base pairs on the vector and insert are complementary, allow the vector and insert to bind to each 
by the ligation reaction. PCR usually generates blunt-ended products and also the digestion with some 
restriction enzymes, meaning that there are no overhanging base pairs in the fragment. The ligation of blunt-
ended products does not involve base-pairing of the protruding ends, instead, the reaction depends on random 
collisions between the blunt-ends. 
Ligation of DNA fragments was performed using T4 DNA Ligase from New England Biolabs® with supplemented 
buffer. Ligation took place under optimized reaction conditions depending on the ligation type (see Table 2). 
Table 2. Reaction mixtures and conditions that were used for either sticky- or blunt-end ligations in the present study. 
Sticky-end Ligation  Blunt-end Ligation 
Components 20µL Reaction 
 
Components 20µL Reaction 
Vector DNA (4kb) 50ng (0.020pmol) 
 
Vector DNA (4kb) 50ng (0.020pmol) 
Insert DNA (1kb) 37.5ng (0.060pmol) 
 
Insert DNA (1kb) 37.5ng (0.060pmol) 
10X T4 DNALigase Buffer 2µL 
 
10X T4 DNALigase Buffer 2µL 
Nuclease-free water up to 20µL 
 
50% PEG 4000 solution 2µL 
T4 DNA Ligase 1µL 
 
Nuclease-free water up to 20µL 
Incubate 1H at RT 
 
T4 DNA Ligase 1µL 
   Incubate ON at RT 
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3.7. GATEWAY® TECHNOLOGY   
The Gateway® Technology is a cloning system based on site-specific recombinases, providing a fast and efficient 
way to insert one or multiple DNA sequences into vectors. Two recombination reactions constitute the basis of 
this technology: the BP reaction, that allows recombination of an attB substrate (attB-PCR product or a 
linearized attB expression clone) with an attP substrate (donor vector) creating an attL-containing entry clone; 
and the LR reaction, that facilitates recombination of an attL substrate (entry clone) with an attR substrate 
(destination vector) thus creating an attB-containing expression clone. 
To perform these recombination reactions we used Gateway® BP Clonase® II Enzyme mix and Gateway® LR 
Clonase® II Enzyme mix for the respective reaction and optimized the manufacturer’s protocol for higher 
efficiency of both reactions (see Table 3). 
Table 3. Optimized reaction mixtures and conditions for both BP and LR reactions. 
BP Reaction 
 
LR Reaction 
Components 8µL Reaction Final Concentration  Components 8µL Reaction Final Concentration 
attB PCR Product or  
Linearized attB Clone 
- 50fmol 
 
5' Entry Clone - 10fmol 
Middle Entry Clone - 10fmol 
Donor Vector - 150fmol 
 
3' Entry Clone - 10fmol 
TE buffer, pH 8.0 up to 8µL 
  
Destination Vector - 150fmol 
BP Clonase™ II  2µL   TE buffer, pH 8.0 up to 8µL  
Incubate ON at RT 
 
LR Clonase™ II  2µL 
 
Proteinase K Solution 1µL  
 
Incubate ON at RT 
Incubate 10 minutes at 37°C 
 
Proteinase K Solution 1µL  
 
 
Incubate 10 minutes at 37°C 
3.8. TRANSFORMATION OF DNA  INTO COMPETENT CELLS 
Transformation is the process by which foreign DNA is introduced into host bacteria. The transformation 
process involves compromising the bacterial membrane permeability (by heat-shock, electric current, etc.), 
allowing the DNA to be introduced into the cytosol of the bacterium. The outgrowth of bacteria following 
transformation allows repair of the bacterial surface and selection of recombinant cells if the newly acquired 
DNA conveys antibiotic resistance to the transformed cells. Transformation of bacteria with plasmids is 
important for replicating plasmids.  
To perform the transformation, we used 25 - 50µL (depending on the strain; 25µL One Shot® ccdB Survival™ 2 
T1R Competent Cells from Invitrogen™; 50µL NZY5α  Competent Cells from NZYTech) of competent cells were 
thawed on ice and 2-5μL of plasmid was added to the cells. Incubation of the cells continued on ice for 30 
minutes and then the cells were heat pulsed at 42°C for 45 seconds followed by 2 minutes incubation on ice. 
300 - 900µL of RT LB medium was added to the cells and following incubation at 37°C for 1 hour. 50/100μL of 
sample was plated out on agar plates with appropriate antibiotic(s) for selection. Plates were incubated at 37°C 
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ON. The resulting colonies were tested by PCR and the positive clones inoculated in 5 - 6mL of LB media with the 
correct antibiotic(s) and cultivated at 37°C in a shaker ON. Plasmids were isolated using the QIAprep® Spin 
Miniprep Kit from Qiage) according to manufacturer’s protocol. The obtained DNA was quantified using a full-
spectrum UV-Vis spectrophotometer, Nanodrop 2000, Thermo Scientific. 
3.9. SEQUENCING 
DNA sequencing is the process of determining the precise order of nucleotides within a DNA strand. Sequence 
data were obtained by LIGHTRUN sequencing, GATC biotech, of the purified plasmid DNA (5µL of DNA 80 - 
100ng/µL) with the desired primer (5µL of 5µM primer). 
3.10. TRANSFECTION OF U2OS  CELLS 
U2OS cells were routinely cultured with Dulbecco's Modified Eagle Medium (DMEM), high glucose, pyruvate, 
from Gilbco™, and incubated at 37°C and 5% CO2 to ensure a stable environment for optimal cell growth.  
Cells were transfected with Lipofectamine™ 3000 Reagent kit from Invitrogen® according to the manufacturer’s 
protocol. In the following day, the medium was changed to eliminate dead cells and toxic reagents. 
3.11. RNA  EXTRACTION 
For RNA extraction from cells we used the RNeasy® from Qiagen and followed the manufacturer’s protocol for 
purification of total RNA from animal cells using spin technology. We used confluent cells in a 12-well plate, 
disrupted in Lysis Buffer complemented with β-mercapthoethanol and homogenized. Ethanol is then added to 
the lysate, creating conditions that promote selective binding of RNA to the RNeasy membrane when the 
sample is applied to the RNeasy Mini spin column. The total RNA binds to the membrane, and contaminants are 
efficiently washed away, which results in high-quality RNA, eluted in 35µL of RNase-free water. All bind, wash, 
and elution steps are performed by centrifugation in a microcentrifuge. The RNA was then quantified using 
Nanodrop 2000, Thermo Scientific. 
3.12. REAL-T IME PCR 
To perform PCR using RNA as a starting template, the RNA must first be reverse transcribed into cDNA in a 
reverse transcription (RT) reaction. We first digested 1µg of the RNA samples with DNase I, RNase-free, from 
Thermo Scientific, following the manufacturer’s protocol, to digest single- and double-stranded DNA. To 
inactivate DNase I we added EDTA to a final concentration of 5mM before heating for 10 minutes at 65°C. 
The cDNA synthesis from RNA was performed using SuperScript® IV First-Strand Synthesis System for RT-PCR 
from Thermo Scientific and following the manufacturer’s protocol. The cDNA samples were diluted 25 times for 
the subsequent quantitative real-time PCR reactions. 
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Quantitative real-time PCR was performed using a 7500 Fast Real-Time PCR System (Applied Biosystems®) with 
Power SYBR® Green PCR Master Mix from Applied Biosystems®, following the standard program. In each well of 
a MicroAmp® Fast Optical 96-well Reaction Plate from Applied Biosystems®, we added 5µL of cDNA sample and 
15µL of qRT-PCR mixture (10µL of Power SYBR® Green PCR Master Mix, 0.5µL of forward and reverse primer’s 
mix at 4µM and 4.5µL of Milli-Q RNase/DNase free water). The expression levels were normalized to GAPDH (a 
housekeeping gene).  
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4. RESULTS 
We designed a PhiC31 integrase-based transgenesis system consisting of two components: the targeting vector 
with a genomic attP landing site and in which PhiC31 is driven by the cytomegalovirus (CMV) early 
enhancer/chicken beta actin (CAG) promoter and the expression vector, an attB site containing vector with an 
insert of interest and a fluorescent marker. When in the genome of mammalian embryonic stem cells, the 
targeting vector drives the expression of PhiC31. The PhiC31 attP and attB sites were designed and positioned 
such that PhiC31-mediated recombination displaces the PhiC31 from the CAG promoter and corresponding start 
codon by the in-frame insertion of the targeting sequence contained in the expression vector. 
4.1. TARGETING VECTOR 
The construction of the targeting vector involves the recombination of three entry vectors, based on the 
Gateway cloning system. 
4.1.1. P5E MCS CAGGS ATTP PHIC31 
The plasmid p5E MCS CAGGS AttP PhiC31 contains the CAGGS promoter, a strong synthetic promoter frequently 
used to drive high levels of gene expression in mammalian expression vectors, and also the AttP PhiC31 landing 
site that allows the integration of the expression vector to occur at this site-specific location. In order to build 
this plasmid, we started by digesting pCAGGS-m2G with SalI and XhoI to excise the CAGGS promoter DNA 
sequence. The digestion was carried out as described in the previous section (see Methods) followed by 
electrophoresis in 1% agarose gel and extraction of the correspondent band (1979bp) (see Figure 6A). At the 
same time, we digested p5E-MCS (T2K228) with XhoI and dephosphorylated the hanging ends with Calf 
Intestinal Alkaline Phosphatase (CIP) from New England Biolabs, following the manufacturer’s protocol. CIP 
catalyzes the dephosphorylation of 5’ and 3’ ends of DNA, preventing religation of the linearized plasmid DNA. 
The product was then run in 1% agarose gel and the DNA extracted from the band (2810bp) (see Figure 6B). The 
ligation then was performed between vector and insert and the product was transformed in Kanamycin plates. 
The colonies that grew were digested with MluI and BamHI to confirm the insertion by electrophoresis following 
MiniPrep (see Figure 6C). 
To introduce the attP PhiC31 landing site into the plasmid, we designed specific oligonucleotides (PhiC31 XhoI 
BamHI F2 and PhiC31 XhoI BamHI R2) that were mixed (5µL top and 5µL bottom oligonucleotide) and annealed 
using an annealing program on a PCR machine (99°C for 15 minutes and slow cooldown, -1°C/15sec until it 
reaches 4°C). This set of primers, when annealed, creates overhangs with XhoI and BamHI restriction sites that 
are relevant for an easy and correct insertion in the plasmid, between the same restriction enzymes’ sites in its 
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sequence. For that, we digested p5E MCS CAGGs with BamHI and XhoI, run in gel and then extracted de DNA 
from the band (4738bp) (see Figure 6D) followed by EtOH precipitation. To set up the ligation, the vector DNA 
pellet was resuspended with the annealed oligonucleotides and we added 1.2µL of Ligase Buffer and 1µL of T4 
DNA Ligase from New England Biolabs® and incubated at RT ON. The product was then transformed in 
Kanamycin plates. To confirm the insertion, the resulting clones were sequenced after MiniPrep. 
 
4.1.2. PME PHIC31 2A 
The Middle Entry plasmid (pME PhiC31 2A) is the plasmid that contains the PhiC31 cassette and the 2A 
sequence. The PhiC31 cassette allows the cell to endogenously express this enzyme and the 2A sequence is a 
protein sequence that enables stoichiometric production of two separate proteins from the same mRNA.  
This plasmid was created by amplifying a previously existing plasmid in the lab (pCS2P+PhiC31o) by PCR with the 
primers pME_PhiC31_F and pME_PhiC31_R to extract the PhiC31 cassette (1909bp) (see Figure 7A). The PCR 
product was run in gel and the DNA was extracted. 
The PhiC31 fragment was then introduced in a donor vector (pDONR221 (T2K218)) by Gateway BP reaction. To 
confirm the insertion we digested the DNA with MluI and AgeI followed by agarose gel electrophoresis (see 
Figure 7B).  
Figure 6. CAGGs fragment cut out from pCAGGs-m2G (RC62), linearization of p5E-MCS (T2K228), digestion to confirm CAGGs insertion in p5E-
MCS (T2K228) and p5E MCS CAGGs linearization in a 1% agarose gel electrophoresis. L corresponds to the 1kb Plus DNA Ladder. (A) Band at 
about 2000bp in lane 1 represents the CAGGs fragment extracted by the plasmid by digestion with SalI and XhoI. (B) Band at about 2800bp in 
lane 1 represents linearized p5E-MCS (T2K228) after digestion with XhoI. (C) Digestion with MluI and BamHI was done to identify positive 
clones with expected bands of 1834, 1325, 932 and 698bp. Lanes 1 to 3 represent defective clones and lane 4 represents a positive p5E MCS 
CAGGs clone that was used in the following steps (D) Band at about 4700bp in lane 1 represents the linearized plasmid after digestion with 
BamHI and XhoI.. 
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To introduce the 2A cassette into the plasmid, we mixed the designed oligonucleotides (2A_BglII_F and 
2A_BglII_R) containing the BglII restriction site (5µL top and 5µL bottom oligonucleotide) and annealed using an 
annealing program on a PCR machine (99°C for 15 minutes and slow cooldown, -1°C/15sec until it reaches 4°C) . 
We digested pME PhiC31 with this same restriction enzyme, run in 1% agarose gel and extracted the DNA 
(4395bp) (see Figure 7C). We then precipitated the plasmid with EtOH and the 2A segment was introduced in 
the linearized plasmid by ligation. To set up the ligation, the vector DNA pellet was resuspended with the 
annealed oligonucleotides and we added 1.2µL of Ligase Buffer and 1µL of T4 DNA Ligase from New England 
Biolabs® and incubated at RT ON. After the reaction, the product was transformed and plated in Kanamycin 
plates and the insertion was confirmed by sequencing. 
4.1.3. P3E NEO POLYA 
This p3E Neo PolyA plasmid contains the Neomycin selection cassette, and the PolyA site that gives stability to 
the mRNA. The Neomycin antibiotic resistance sequence will allow the posterior selection of the positive clones.  
This plasmid was obtained by PCR of the pROSA Dest1 to amplify the Neo PolyA with the p3E F5 Felicia and p3E 
R5 Felicia primers. The product was subsequently run in an agarose gel and the band was extracted according to 
the protocol (2164bp) (see Figure 8A).  
Figure 7. PhiC31 fragment cut out from pCS2P+PhiC31o, digestion of pME PhiC31 to confirm insertion and linearized pME PhiC31 in a 1% 
agarose gel electrophoresis. L corresponds to the 1 kb size marker. (A) Band at about 1900bp in lane 1 represents the PhiC31 fragment 
extracted by the pCS2P+PhiC31o plasmid by PCR with the pME_PhiC31_F and pME_PhiC31_R primers. (B) Lane 1 represents the the plasmid 
with the PhiC31 insertion (pME PhiC31) digested with MluI and AgeI to confirm the insertion. (C) Band at about 4400bp represents the 
linearized pME PhiC31 used to introduce the 2A cassette. 
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A BP reaction was then performed between the PCR product and a donor vector (pDONRP2R-P3 (T2K220)) to 
create the p3E Neo PolyA plasmid that was then transformed and plated in Kanamycin plates, followed by 
Miniprep. The clones were confirmed by restriction enzyme digestion with BamHI and ApaLI (see Figure 8B).  
4.1.4. PROSA26 DV2 
The transgene insertion into the ROSA26 locus by targeting has emerged as a favored solution to gain better 
control on gene expression. This gene is globally expressed in wild-type embryonic stem cells and does not 
undergo silencing, thereby representing an ideal site for directed integration of transgenes, providing high 
targeting efficiency and ubiquitous transgene expression at moderate levels. The drawback of this approach was 
the increased complexity of target vector building but to streamline the production of conditional ROSA26 
targeting vectors, Nyabi et al. have generated a Gateway ROSA26 destination vector (pROSA26-DV2) as a 
substrate for the efficient insertion of cDNAs available as attR4-cDNA-attR2 entry clones. This vector has the 
ROSA26 genomic flanking arms that allow homologous recombination with the traditional cloning.  
4.1.5. LR REACTION 
Next, we performed the LR reaction between the three entry clones previously constructed and the destination 
vector. This reaction was successfully performed using 10fmol of each entry vector and 20fmol of the 
destination vector. Because the last vector is too large (>11000bp), we previously linearized it by digestion with 
XbaI, for more efficient recombination. The transformation was then done but, instead of LB medium, we added 
250µL of SOC medium to the cells and incubated at 37°C for 3 hours. This medium is richer than LB in terms of 
nutrients and results in higher transformation efficiency of plasmids. Next, we did a colony PCR with the primers 
Figure 8. Neo PolyA fragment cut out from pROSA Dest1 and DNA digestion to confirm Neo PolyA insertion in a 1% agarose gel 
electrophoresis. L corresponds to the 1kb Plus DNA Ladder. (A) Band above 2000bp in lane 1 represents the Neo PolyA fragment extracted 
from the plasmid by PCR with the p3E F5 Felicia and p3E R5 Felicia primers. (B) Digestion with ApaLI and BamHI was done to identify positive 
clones with expected bands of 1880, 1598 and 1254bp. All lanes correspond to positive p3E Neo PolyA clones. 
23 
 
 
pME Color-MYH9 R and pME_PhiC31_Seq3 and run in a 1% agarose gel to check for positive clones (802bp) (see 
Figure 9). The plasmid was then confirmed by sequencing. 
4.2. EXPRESSION VECTOR 
The expression vector is the plasmid of interest that the user wants to insert in the targeting vector. To validate 
our strategy, we created a simple expression vector to be tested in cells. The backbone of this plasmid can be 
always used for the expression as it has the attachment site AttB PhiC31 that will allow it to be inserted in the 
targeting vector and the Puromycin selection cassette that makes possible the selection of the positive cells. The 
gene of interest (GOI) can be inserted in the backbone of this plasmid by a simple BP reaction.  
To create this plasmid, we started by phosphorylating and annealing the AttB PhiC31 oligonucleotides (pD221-
AttB site-F and pD221-AttB site-R). The phosphorylation adds a phosphate group to the 5' end of a DNA 
molecule making the subsequent ligation steps more efficient and, because the enzyme phosphorylates single-
stranded DNA more efficiently than double stranded DNA and heat inactivation may be close to the melting 
temperature of the annealed oligonucleotides, this step is better performed prior to annealing the 
complementary oligonucleotides. The phosphorylation was performed using T4 Polynucleotide Kinase from 
Thermo Scientific™ and following the protocol for Phosphorylation™ of DNA. To anneal the oligonucleotides, we 
mixed 5µL of each phosphorylated oligonucleotide (forward and reverse) with 90µL of dH2O and used an 
annealing program on a PCR machine (99°C for 15 minutes and slow cooldown, -1°C/15sec until it reaches 4°C). 
This DNA sequence was then introduced in a donor vector (pDONR221 (T2K2018)) by cutting the plasmid with 
ApaI and AflII (4749bp) (see Figure 10A) and consequent ligation of the two fragments. The product was 
transformed in One Shot® ccdB Survival™ 2 T1R Competent Cells from Invitrogen™ in Kanamycin plates and the 
insertion was confirmed by PCR with M13F and ccdB Rev oligonucleotides (see Figure 10B).  
Figure 9. PCR to confirm LR reaction between p5E MCS CAGGs AttP PhiC31, pME PhiC31 2A, p3E Neo PolyA and pROSA26 DV2, run in a 1% 
agarose gel electrophoresis. L corresponds to the 1kb DNA Ladder. The band below 1000bp in each lane represent the 802bp fragment of 
DNA that resulted from the PCR using pME Color-MYH9 R and pME_PhiC31_Seq3 oligonucleotides to identify positive clones. 
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Figure 10. pDONR221 (T2K2018) digestion and PCR to confirm AttB PhiC31 insertion in the plasmid in a 1% agarose gel electrophoresis. L 
corresponds to the 1kb Plus DNA Ladder. (A) Band below 5000bp in lane 1 represents the linearized plasmid after digestion with ApaI and 
AflII. (B) PCR using M13F and ccdB Rev oligonucleotides to identify positive clones. Size with insert is 786bp and size without insert is 716bp. 
Lanes 6 and 10 correspond to positive pDONR221 AttB PhiC31 clones. 
After confirming this insertion, we introduced the PGK Puro PA cassette. This sequence was amplified from a 
previously existing plasmid in the lab (p3E PGK Puro PA BP) by PCR and using the suitable primers (p3E-PGK-
Puro-F and p3E-PGK-Puro–R). At the same time, the pDONR221 AttB PhiC31 plasmid was digested with EcoRV, 
that creates blunt ends, and then dephosphorylated using FastAP™ Thermosensitive Alkaline Phosphatase from 
Thermo Scientific™, following the manufacturer’s protocol. This enzyme catalyzes the release of 5'- and 3'- 
phosphate groups from DNA preventing the recircularization of the cloning vector DNA during ligation. Both PCR 
product and linearized plasmid were run in 1% agarose gel electrophoresis and the DNA extracted (1784 and 
4832bp, respectively) (see Figure 11A). The PGK Puro PA cassette was phosphorylated using T4 Polynucleotide 
Kinase from Thermo Scientific™ and following the manufacturer’s protocol. The two fragments were then 
ligated, transformed in One Shot® ccdB Survival™ 2 T1R Competent Cells from Invitrogen™ and plated in 
Kanamycin + Chloramphenicol agar plates. The insertion was confirmed by PCR with ClamR Fw and M13R2 (see 
Figure 11B) and posterior sequencing, originating the backbone for the Expression Vector, named pDONR221 
AttB(PhiC31) PGK PuroPA.  
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As mentioned before, the following step is “user dependent” as it will allow the introduction of the GOI in the 
previous plasmid. Here, we inserted a GTS-mCherry.2A-H2B-eGFP cassette by amplifying by PCR a construct 
(pUC57-Amp_VEcad_GTS.mCherry-2A-H2B.eGFPpA_FRT.Neo.FRTpA) that was previously tested in our 
laboratory and that has shown positive results. By using this cassette in our plasmid, we would be able to 
validate its insertion into the targeting vector by accessing the fluorescence of the cells as they would express 
the red fluorophore in the nucleus (GTS-mCherry) and the one green one in the Golgi apparatus (H2B-eGFP), 
what would give us a rapid visible readout of the efficacy of our technique. In order to do this, we used designed 
oligonucleotides that conduct the creation of the AttB1 and AttB2 sites for the posterior BP reaction (pME-
GTS.Color-F BP and pME-H2B.eGFP-R BP). The PCR product was run in 1% agarose gel electrophoresis and the 
DNA extracted from the band (2285bp) (see Figure 12A). The BP reaction was then performed between this 
product and the pDONR221 AttB PhiC31 PGK PuroPA plasmid, transformed in Kanamycin agar plates and the 
insertion confirmed by PCR (1117bp)(see Figure 12B) and sequencing. 
 
Figure 11. PGK Puro PA fragment cut out from p3E PGK Puro PA BP and digestion of pDONR221 AttB PhiC31 and PCR to confirm PGK Puro PA 
insertion in pDONR221 AttB PhiC31 plasmid in a 1% agarose gel electrophoresis. L, in A, corresponds to the 1kb Plus DNA Ladder and in B to 
the 1kb DNA Ladder. (A) Band at about 2000bp in lane 1 represents the PGK Puro PA fragment amplified from p3E PGK Puro PA BP plasmid 
by PCR with p3E-PGK-Puro-F and p3E-PGK-Puro–R oligonucleotides. Band at about 5000bp in lane 2 represents linearized pDONR221 AttB 
PhiC31 after digestion with EcoRV. (B) PCR was performed with ClamR Fw and M13R2 oligonucleotides. Lanes 1 to 22, 25 and 34 correspond 
to negative clones, which did not incorporate the PGK Puro PA fragment (590bp). Lane 44 the remaining lanes between 2000 and 2500bp, 
could both possible represent a positive pDONR221 AttB PhiC31 PGK Puro PA clone (2374bp). We sequenced both lane 43 and lane 44 and 
confirmed that the positive clone was on lane 44 being that the other lanes correspond to nonspecific bands. 
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4.3. TEST CONSTRUCTS IN U2OS  CELLS 
The human osteosarcoma U2OS cell line is one of the first generated cell lines and is widely used in various 
areas of biomedical research as they grow fast and have high transfection efficiency. Therefore, we used this cell 
line to test our constructs before using them in embryonic stem cells. 
For the U2OS cells’ transfection with the targeting vector, the cells were seeded in two wells in a 6 well plate 
24h prior transfection and the cells from one of the wells were transfected with approximately 2µg of DNA 
when they reached a 30-50% confluence. The non-transfected cells served as control. We maintained the cells 
in culture for posterior experiments. 
To check the efficiency of our strategy we did a Neomycin selection of the transfected cells in culture with 
DMEM complemented with G418 (500µg/µL) from Invivogen. This killed the non-transfected cells that were 
removed in the subsequent medium changes. When cells were confluent enough, we extracted their RNA to 
check for PhiC31 expression by RT-PCR using the primers qPCR PhiC31 F and qPCR PhiC31 R. We used GAPDH as 
housekeeping gene and the expression levels of PhiC31 in transfected and non-transfected cells were 
normalized to these values (see Figure 13). 
Figure 12. GTS Cherry H2B eGFP fragment cut out from pUC57-Amp_VEcad_GTS.mCherry-2A-H2B.eGFPpA_FRT.Neo.FRTpA and PCR to 
confirm GTS Cherry H2B eGFP cassette insertion in pDONR221 AttB PhiC31 PGK Puro PA plasmid in a 1% agarose gel electrophoresis. L 
corresponds to the 1kb Plus DNA Ladder. (A) Band above 2000bp in lane 1 represents the GTS Cherry H2B eGFP fragment amplified from 
pUC57-Amp_VEcad_GTS.mCherry-2A-H2B.eGFPpA_FRT.Neo.FRTpA plasmid by PCR with pME-GTS.Color-F BP and pME-H2B.eGFP-R BP 
oligonucleotides. (B) PCR was done with ccdB Rev, M13F and Cherry-polyA_AttP5-B2 oligonucleotides. Lanes 2 to 9 correspond to negative 
clones (786bp). Lane 1 represents an apparently positive pDONR221 AttB PhiC31 PGK Puro PA GTS Cherry H2B eGFP clone (1117bp). 
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Figure 13. Real‐time PCR plot of the cDNA of U2OS cells transfected and not transfected with the targeting vector. Gene‐specific primers 
were designed to the hairpin of the PhiC31 mRNA precursors (qPCR PhiC31 F and qPCR PhiC31 R). The cDNA from the cells was amplified 
with SYBR green detection. For each condition, we made technical duplicates and the Ct values described represent the mean values. The 
grey plots corresponds to control (light grey, CT = 16.7) and transfected cells (dark grey, CT = 16.9) using GAPDH primers, the blue plot to 
the control cells with the PhiC31 primers (CT undetermined), and the yellow plot to the transfected cells also with the PhiC31 primers (CT = 
21.2). CT threshold = 0.2. 
The RT-PCR revealed that the control cells do not express PhiC31 (CT undetermined) contrarily to the 
transfected cells (CT = 21.2), confirming the efficiency of the insertion of our plasmid into the cells (see Figure 
14). 
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Figure 14. PhiC31 gene expression in Ct values relative to housekeeping gene obtained by real-time PCR. Control cells are represented in 
blue (not visible) and cells transfected with the targeting vector in yellow.  
After confirming that our cells were expressing the enzyme, we tested the efficacy of the expression vector in 
these cells. In order to do this, we transfected the cells with this vector and checked for mCherry fluorescence. 
Both control cells and cells transfected with the targeting vector were split to 3 wells on a 24-well plate and 
cultured on coverslips pre-treated with 0.2% gelatin coating. For both cell “types” we created two conditions: 
non-transfected (control) and transfected with 500ng of DNA. Three days after transfection, cells were fixed in 
1% PFA complemented with calcium chloride and magnesium chloride (0.05%), stained with DAPI, that labels 
the cell nuclei in blue, and GOLPH4, that labels the Golgi apparatus in green, and mounted on microscopy slides 
using MOWIOL with DABCO. The cells were then analyzed using a motorized widefield fluorescence microscope, 
Zeiss Axiovert 200M, and the MetaMorph® software (see Figure 15). We were able to see that, when 
transfected with the expression vector, not only the cells with the targeting vector express the mCherry 
fluorophore, but also the control cells (in red). We can also see that this red label is mainly located in the nuclei 
of the cells and not on the Golgi apparatus as we would expect. 
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Figure 15. Microscopy images of the control cells (left) and cells transfected with the targeting vector (right), both transfected with the 
expression vector. Top images show merged channels of DAPI labelling the cell nuclei in blue, GOLPH4, staining the Golgi apparatus in green 
and mCherry in red, due to the transfection with the expression vector. The red fluorescence is mainly located in the nuclei of the cells but we 
can also see some Golgi apparatus stained with mCherry. Scale bar: 20μm. 
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5. DISCUSSION 
When constructing the plasmids mentioned above, we faced some problems that slowed down the process, 
besides the drawbacks that are already attached to this sort of cloning methods.  
The cloning of PCR amplified fragments into a plasmid vector is a routine procedure in recombinant DNA 
cloning, but all PCR fragments will not clone with the same efficiency and the complexity of the cloning strategy 
needs to be considered. The p5E CAGGS PhiC31 plasmid was the one with which we struggled the most. Our 
first strategy was based on the amplification of the CAGGS promoter from the pCAGGS-G2m plasmid by PCR 
using specific primers. This attempt failed due to the fact that the 3’ part of this promoter has a high GC content 
and is thus refractory to PCR amplification. We then tried four different primers combinations, again, 
unsuccessfully. Our next step was to try the same strategy but, this time, using two other plasmids containing 
the promoter (pCAGGS vector in H79-1H3 and pLB2-CAG.P2G plasmid) and three other primer combinations but 
they were still not able to amplify the CAGGS promoter.  
We then tried another PCR approach, the ‘slowdown’ PCR, 
which, theoretically, allows the amplification of extremely 
GC-rich (> 83%) targets, relying on combination of a novel 
standardized cycling protocol with varying temperature 
ramping rates [82]. ‘Slowdown’ PCR was used with a 
generally lowered ramp rate at 2.5°C/sec and especially a 
small cooling rate for reaching annealing temperature at 
1.5°C/sec. It comprises an initial cycling step of 95°C for 5min 
for complete first-strand separation. Amplifications are run 
for 48 cycles with 30sec denaturation at 95°C, 30sec 
annealing with a progressively lowered temperature from 
70°C to 53°C at a rate of 1°C every third cycle, and a primer 
extension of 40sec followed by 15 additional cycles with an 
annealing temperature of 58°C (see Figure 16).  
However, despite our efforts, the promoter’s amplification 
still did not work. Our last option was to change strategy and 
so we followed the “classic” cloning approach described in 
the previous section that worked after many attempts and 
optimizations. 
Figure 16. ‘Slowdown’ PCR cycling method. Amplifications 
are run for 48 cycles with 30sec denaturation at 95°C, 30sec 
annealing with a progressively lowered temperature from 70 
to 53°C at a rate of 1°C every third cycle, and a primer 
extension of 40sec, followed by 15 cycles with an annealing 
temperature of 58°C. Ramp rates: 2.5°C/1.5°C/sec. Image 
adapted from [82]. 
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Other construct that was not straightforward was the p3E Neo PolyA. Following the described strategy, our first 
effort to build this plasmid, in the end, revealed a problem. When designing the primers to amplify the Neo 
PolyA cassette we did not take into account that those oligonucleotides would lead to a segment that was not in 
frame. We then redesigned another set of primers and repeated the procedure. 
Another step that took us a lot of time was the pROSA26-DV2 itself. This plasmid was ordered in the past and, 
therefore, existed in the lab for some time. When our many attempts to perform the LR reaction between it and 
the other three plasmids failed, we started doubting about this plasmid and we sequenced it. The sequencing 
results revealed a lot of mutations at important sites of this vector (namely at attachment sites) that decreased 
the efficiency of the reaction and that probably explained why we were not able to perform the reaction. We 
ordered a new plasmid but when amplifying this plasmid we faced other problem: the need of a special ccdB-
resistant strain for propagation, being that the Invitrogen One Shot ccdB Survival 2 T1R Competent Cells (that 
we usually use in our lab) are not recommended for this plasmid and, therefore, we had to order Escherichia coli 
K12xB DB3.1 from BCCM/LMBP Plasmid Collection (Accession number LMBP 4098). We were then able to 
amplify the plasmid, under special conditions (30°C in Ampicillin and Chloramphenicol) and then repeat the 
protocol for the LR reaction. This time, after some tries and optimizations, it worked as expected. 
For the expression plasmid, we projected the insertion of a GTS-mCherry.2A-H2B-eGFP cassette, which would 
give red fluorescence to the Golgi apparatus and green labelling to the nuclei of the cells containing the plasmid. 
In the last step, the BP reaction between this fragment and the pDONR221 AttB PhiC31 PGK PuroPA, it was very 
difficult to obtain colonies after transformation and even more difficult to get a positive clone for the insertion. 
In the end, we were surprised to know, by sequencing, that the H2B-eGFP segment was not inserted in the 
plasmid and there is no logical explanation for that to occur. Due to the difficulties that we previously 
encountered to successfully insert this cassette into the plasmid and the time constraints for this thesis 
submission, we decided to try it as it is as the GTS-Cherry fragment would be enough to prove the efficiency of 
our technique. 
The cell transfection with the targeting vector did not give us a great input on the efficacy and efficiency of this 
plasmid.  We confirmed that these cells expressed PhiC31 mRNA, however, the expression vector seemed to be 
very leaky in terms of expression and localization of the fluorescent protein. When we transfected the control 
cells (cells without PhiC31 expression) with the pDONR221 AttB PhiC31 GTS mCherry PGK PuroPA showed high 
number of cells expressing red fluorescence. Moreover, the fluorescence was supposed to be on the Golgi 
apparatus and not on the nuclei of the cells as we can see it. This pattern of expression was very similar to what 
we observed in cells expressing PhiC31. This was very surprising as we tested this expression cassette previously, 
and gave us the expected results (see Figure 17). This probably occurred due to an unknown defect on the 
plasmid, which was not integrally sequenced. The problem arouse very likely when performing the BP reaction 
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between the GTS-Cherry.2A-H2B-eGFP cassette and the correspondent donor vector. A possible explanation, 
which we are trying to confirm, was the insertion of the human histone H2B cassette in the same reading frame 
as mCherry, making the nuclei of the cells, and not the Golgi apparatus, express the red fluorophore. Given that 
we cannot conclude about the efficiency and efficacy of our strategy with the current expression vector, we are 
going to start generating a new expression vector from the beginning with a different strategy in mind. 
Nevertheless, the present results with the targeting vector were satisfactory and, therefore, we believe that, in 
a close future, we will be able to validate our work in U2OS cells and, posteriorly apply it to embryonic stem 
cells. Because the technology and knowledge needed to perform this is not available in our lab, a specialized 
company, PolyGene Transgenetics, will ensure it. 
The efficiency, ease-of-use, and versatility that can possibly be obtained with our PhiC31-based integration 
system represents an important advance in transgenesis approaches and opens up the possibility that will 
strongly facilitate such studies. Our strategy has a number of important characteristics that makes it highly 
promising. First, it carries out unidirectional recombination reactions, thus making the insertion of plasmid DNA 
efficient, permanent and stable in cells. Second, due to an endogenous source of PhiC31 integrase, we 
overcome the need of injecting in vitro synthesized integrase mRNA, eliminating time and costs required for 
mRNA production and significantly reducing complications associated with the injection process, therefore 
enhancing the integration rates. Third, there is no limit to the size of the plasmid to be integrated into the 
genome, allowing the insertion of large and/or multiple genes. Fourth, the predetermined integration sites 
effectively eliminate the time and effort needed to map transgene insertions. Lastly, this versatile system also 
offers the possibility to have an immediate visible readout to permit rapid selection for precise integration 
events. 
Due to its high versatility, an unlimited number of constructs can be used and, therefore, we aim to build a 
library of expression vectors that are interesting for our lab, for example, vectors that express proteins linked to 
Figure 17. U2OS cells transfected with a construct comprising the GTS (Golgi-specific targeting sequence) fused to mCherry, a 2A self-
cleavage peptide, and histone H2B fused to eGFP. We can observe the expression of mCherry in Golgi apparatus as well as eGFP inside the 
nucleus of these cells. 
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the cytoskeleton to see the dynamic of endothelial cells in a sprouting assay and components that affect the 
VEGF/Notch signaling to study the competition of cells for the tip position. It would also be interesting to 
construct expression vectors that knockdown endogenous genes with shRNAs to generate stable knockdown 
cell lines avoiding the common adenoviral delivery of shRNA, which has well-known toxic effects. In our 
construct, after recombination, the promoter is constitutively driving the targeted protein so all the cells will be 
expressing it but, complementarily, it is possible to develop a vector with a temporal activation of the targeting 
genes by adding a Lox-Stop-Lox sequence and by crossing this mouse line with endothelial-specific Cre lines, 
allowing controlling both spatial and temporal activation. By adding Tamoxifen, Cre will be activated and will 
recombine this Lox-Stop-Lox and eliminate the Stop codon, meaning that after recombination, the cells that 
recombine will start to express that gene. 
In summary, we strongly believe that the system presented in this study has the potential to simplify, accurate 
and accelerate cell genome editing processes what will allow the test of many different constructs that can be 
used in diverse applications. Not only by creating this embryonic stem cell line, but also, through the conception 
of different mouse lines, we consider that this strategy will facilitate many approaches in our laboratory and 
hopefully, contribute significantly to other fields of biology in a wide range of assays, allowing other researchers 
to optimize genome editing in their specific systems. 
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APPENDIX 
PRIMERS 
Table A1. Sequences of all primers used for either PCR amplifications or sequencing analysis. Primers used for sequencing are marked with *.  
All primers were imported from Sigma Aldrich®. 
Primer Name 
Tm 
(°C) 
Sequence (5' → 3') 
2A_BglII_F 95,6 GATCGGAGGGCAGGGGAAGTCTTCTAACATGCGGGGACGTGGAGGAAAATCCCGGGCCCA 
2A_BglII_R 94,6 GATCTGGGCCCGGGATTTTCCTCCACGTCCCCGCATGTTAGAAGACTTCCCCTGCCCTCC 
CAGGs PhiC31 Seq1* 58,7 TATGGAGTTCCGCGTTAC 
CAGGs PhiC31 Seq2* 58,6 CGTTCTGCTTCACTCTCC 
CAGGs PhiC31 Seq3* 62,3 TGGTTTAATGACGGCTCG 
CAGGs PhiC31 Seq4* 60,7 GAAGAAGGCATGAACATGG 
Caggs Seq1* 61,3 AACCGTATTACCGCCTTTG 
Caggs Seq2* 66,5 CGTAATGGCTGGCCTGTTG 
Caggs Seq3* 58,9 GTGTCTTACCGGGTTGG 
ccdB Rev* 63,0 CCACCGCGAAAATGACATC 
Cherry-polyA_AttP5-B2*  64,7 TGATGTTGACGTTGTAGGCG 
ClamR Forw* 59,0 CGATGCCATTGGGATATATC 
GAPDH_Fw 66,5 GTCAAGGCTGAGAACGGGAA 
GAPDH_Rv 64,5 TGGACTCCACGACGTACTCA 
M13F* 61,8 TGTAAAACGACGGCCAGT 
M13R2* 62,1 CAGGAAACAGCTATGACCATG 
Neo pA Seq1* 62,8 TCGACGTTGTCACTGAAGC 
Neo pA Seq2* 61,2 CGCCTTCTTGACGAGTTC 
Neo pA Seq3* 60,5 GTCGCAGATCCAGACATG 
p3E PGK-Puro-pA F 83,2 CGATCTGGATCCGCTCAGACGAGTCGGATCTCC 
p3E PGK-Puro–pA R 77,9 GCTGATGGATCCAGGATAGCTAGAGCCAGACATG 
p3E Seq Neo F* 61,5 ATGAACTGCAGGACGAGG 
p3E-F5 Felicia 88,1 GGGGACAGCTTTCTTGTACAAAGTGGGCCAATATGGGATCGGCCATTGA 
p3E-R5 Felicia 82,2 GGGGACAACTTTGTATAATAAAGTTGGGTTCCGGATCAGCTTGATGG 
p5E CAGGs Seq2 CF* 64,2 AAAGCCTTAAAGGGCTCCG 
p5E CAGGs Seq3 CF* 63,5 TGCCTTTTATGGTAATCGTGC 
pD221-AttB site–F 66,5 TTAAGTACTCGAAGCCGCGGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTACTCCACCTCACCCATCTCGGCC 
pD221-AttB site–R 68,0 GAGATGGGTGAGGTGGAGTACGCGCCCGGGGAGCCCAAGGGCACGCCCTGGCACCCGCACCGCGGCTTCGAGTAC 
PhiC31 XhoI-BamHI F2 89,1 TCGAGGCCCCCAACTGGGGTAACCTTTGAGTTCTCTCAGTTGGGGGAG 
PhiC31 XhoI-BamHI R2 88,2 GATCCTCCCCCAACTGAGAGAACTCAAAGGTTACCCCAGTTGGGGGCC 
pME Color-MYH9 R 81,3 AGAAAGCTGGGTTGAACCTGCGTGCAATCCATC 
pME PhiC31 Seq1* 67,0 GTGTCCCGGTTCAGCAGG 
pME PhiC31 Seq3* 64,0 ATCACCGGCCTGTGTAAGAG 
pME PhiC31 Seq4* 64,4 CAAGAGGGTGTTCGTGGG 
pME_PhiC31_F 87,1 GGGGACAAGTTTGTACAAAAAAGCAGGCTGCCGCCACCATGGATACCTA 
pME_PhiC31_R 83,3 GGGGACCACTTTGTACAAGAAAGCTGGGTAGATCTCACTTTCCGCTTTTTCTTAG 
pME-GTS.Color-F BP 85,8 GGGGACAAGTTTGTACAAAAAAGCAGGCTTACCAGATCAGCTCCTCCACGAAG 
pME-H2B.eGFP-R BP 85,0 GGGGACCACTTTGTACAAGAAAGCTGGGTTAGGGTGAACATACGCGTCTT 
qPCR PhiC31 F 63,7 CGTGATGACCAGCAAGAGAG 
qPCR PhiC31 R 66,5 CGGCCATGCTCACATTACAG 
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RESTRICTION ENZYMES 
Table A2. Recognition sequences of all restriction enzymes used in this study. 
Enzyme Recognition Sequence Buffer Vendor 
AflII C/TTAAG Orange Thermo Scientific 
AgeI A/CCGGT NEBuffer 1.1 New England BioLabs 
ApaI GGGCC/C CutSmart Buffer New England BioLabs 
ApaLI G/TGCAC Tango Thermo Scientific 
BamHI G/GATCC Buffer BamHI Thermo Scientific 
BglII A/GATCT Orange Thermo Scientific 
EcoRV GAT/ATC NEBuffer 3.1 New England Biolabs 
MluI A/CGCGT NEBuffer 3.1 New England BioLabs 
SalI G/TCGAC NZY Buffer A NZY Tech 
XhoI  C/TCGAG Red Thermo Scientific 
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CLONING PROCESS OVERVIEW 
 P5E MCS CAGGS ATTP PHIC31 
Figure A1. Schematic overview of the cloning process that resulted in the generation of the p5E MCS CAGGs AttP PhiC31 plasmid. The figure 
shows the different vectors used and the strategy followed. 
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PME PHIC31 2A 
 
  
Figure A2. Schematic overview of the cloning process that resulted in the generation of the pME PhiC31 2A plasmid. The figure shows the 
different vectors used and the strategy followed. 
45 
 
 
P3E NEO POLYA 
  Figure A3. Schematic overview of the cloning process that resulted in the generation of the p3E Neo PolyA plasmid. The figure shows the 
different vectors used and the strategy followed. 
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PROSA26-DV2-CAGGS-PHIC31-NEOPA 
 
Figure A4. Schematic overview of the LR reaction (Gateway) between the three created entry vectors and the destination vector (pROSA26 
DV2) that resulted in the generation of the targeting vector. 
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PDONR221 ATTB PHIC31 PGK PURO PA GTS CHERRY 
 
Figure A5. Schematic overview of the cloning process that resulted in the generation of the pDONR221 AttB PhiC31 PGK Puro PA GTS Cherry 
plasmid. The figure shows the different vectors used and the strategy followed. 
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PLASMID MAPS AND SEQUENCES 
P3E NEO POLYA 
 
Figure A6. p3E Neo PolyA vector map. Features were automatically annotated using SnapGene® Software. 
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P3E PGK PURO PA BP 
 
Figure A7. p3E PGK Puro PA BP vector map. Features were automatically annotated using SnapGene® Software. 
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P5E-MCS (T2K228) 
 
Figure A8. p5E-MCS (T2K228) vector map. Features were automatically annotated using SnapGene® Software. 
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P5E MCS CAGGS ATTPHIC31 
 
Figure A9. p5E MCS CAGGS AttP PhiC31 vector map. Features were automatically annotated using SnapGene® Software. 
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PCAGGS-M2G 
 
Figure A10. pCAGGS-m2G vector map. Features were automatically annotated using SnapGene® Software. 
56 
 
 
 
  
57 
 
 
PCS2P+PHIC31O 
 
Figure A11. pCS2P+PhiC31o vector map. Features were automatically annotated using SnapGene® Software. 
 
58 
 
 
 
  
59 
 
 
PDONR221 (T2K218) 
 
Figure A12. pDONR221 (T2K218) vector map. Features were automatically annotated using SnapGene® Software. 
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PDONR221 ATTB PHIC31 PGK PURO PA GTS CHERRY 
 
Figure A13. pDONR221 AttB PhiC31 PGK Puro PA GTS Cherry vector map. Features were automatically annotated using SnapGene® Software. 
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PDONRP2R-P3 (T2K220) 
 
Figure A14. pDONRP2R-P3 (T2K220) vector map. Features were automatically annotated using SnapGene® Software. 
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PME PHIC31 2A 
 
Figure A15. pME PhiC31 2A vector map. Features were automatically annotated using SnapGene® Software. 
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PROSA26 DEST 
 
Figure A16. pROSA26 Dest vector map. Features were automatically annotated using SnapGene® Software. 
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PROSA26-DV2 
 
Figure A17. pROSA26-DV2 vector map. Features were automatically annotated using SnapGene® Software. 
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PROSA26-DV2-CAGGS-PHIC31-NEOPA 
 
Figure A18. pRosa26-DV2-CAGGS-PhiC31-NeoPA vector map. Features were automatically annotated using SnapGene® Software. 
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PUC57-AMP_VECAD_GTSMCHERRY-2A-H2BEGFPPA_FRT.NEO.FRTPA 
 
Figure A19. pUC57-Amp_VEcad_GTSmCherry-2A-H2BeGFPpA_FRT.Neo.FRTpA vector map. Features were automatically annotated using 
SnapGene® Software. 
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